KR101871133B1 - 벤즈옥사제핀 화합물의 제조 방법 - Google Patents

벤즈옥사제핀 화합물의 제조 방법 Download PDF

Info

Publication number
KR101871133B1
KR101871133B1 KR1020177016062A KR20177016062A KR101871133B1 KR 101871133 B1 KR101871133 B1 KR 101871133B1 KR 1020177016062 A KR1020177016062 A KR 1020177016062A KR 20177016062 A KR20177016062 A KR 20177016062A KR 101871133 B1 KR101871133 B1 KR 101871133B1
Authority
KR
South Korea
Prior art keywords
compound
formula
bromo
reacting
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177016062A
Other languages
English (en)
Korean (ko)
Other versions
KR20170070270A (ko
Inventor
레미 엔젤라우드
다니엘 알 뷰드리
다이앤 이 카레라
수샨트 말호트라
트래비스 레마척
프레데릭 세인트-진
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20170070270A publication Critical patent/KR20170070270A/ko
Application granted granted Critical
Publication of KR101871133B1 publication Critical patent/KR101871133B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177016062A 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법 Expired - Fee Related KR101871133B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024484A Division KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016976A Division KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Publications (2)

Publication Number Publication Date
KR20170070270A KR20170070270A (ko) 2017-06-21
KR101871133B1 true KR101871133B1 (ko) 2018-06-25

Family

ID=50241450

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177016062A Expired - Fee Related KR101871133B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020187016976A Withdrawn KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020157024484A Expired - Fee Related KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187016976A Withdrawn KR20180070715A (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법
KR1020157024484A Expired - Fee Related KR101821468B1 (ko) 2013-03-13 2014-03-12 벤즈옥사제핀 화합물의 제조 방법

Country Status (15)

Country Link
US (1) US9303043B2 (https=)
EP (3) EP3845540A1 (https=)
JP (6) JP6363120B2 (https=)
KR (3) KR101871133B1 (https=)
CN (2) CN108929333A (https=)
AR (1) AR095365A1 (https=)
AU (3) AU2014230812B2 (https=)
BR (1) BR112015020716A2 (https=)
CA (6) CA2897618A1 (https=)
IL (1) IL240793A0 (https=)
MX (1) MX2015011438A (https=)
NZ (1) NZ711192A (https=)
RU (2) RU2018109979A (https=)
SG (2) SG10201706760YA (https=)
WO (1) WO2014140073A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180093138A (ko) 2013-12-16 2018-08-20 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
KR20190036549A (ko) * 2016-07-29 2019-04-04 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 제조 방법
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018109204A1 (en) 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507577A (ja) 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
US20110076292A1 (en) * 2009-09-28 2011-03-31 Nicole Blaquiere Benzoxazepin pi3k inhibitor compounds and methods of use
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
WO2000024720A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
KR20040024564A (ko) 2001-07-12 2004-03-20 아베시아 리미티드 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
JP2010516680A (ja) * 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
US8716483B2 (en) * 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
MX2010010659A (es) 2008-03-31 2010-10-26 Genentech Inc Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
WO2011053688A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
NO3175985T3 (https=) * 2011-07-01 2018-04-28
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507577A (ja) 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
US20110076292A1 (en) * 2009-09-28 2011-03-31 Nicole Blaquiere Benzoxazepin pi3k inhibitor compounds and methods of use
JP2013505917A (ja) 2009-09-28 2013-02-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use

Also Published As

Publication number Publication date
KR101821468B1 (ko) 2018-01-23
EP3404032A2 (en) 2018-11-21
AU2014230812A1 (en) 2015-09-03
EP2970329A1 (en) 2016-01-20
JP2019031493A (ja) 2019-02-28
KR20150119033A (ko) 2015-10-23
JP6442005B2 (ja) 2018-12-19
EP3404032B1 (en) 2025-07-02
HK1215433A1 (zh) 2016-08-26
CA3005103A1 (en) 2014-09-18
JP6663459B2 (ja) 2020-03-11
JP2018008959A (ja) 2018-01-18
SG11201507394RA (en) 2015-10-29
RU2649976C2 (ru) 2018-04-06
EP3404032A3 (en) 2019-03-13
AU2018201393A1 (en) 2018-03-15
IL240793A0 (en) 2015-10-29
CN105377856B (zh) 2018-05-22
KR20180070715A (ko) 2018-06-26
AU2014230812B2 (en) 2016-04-07
AU2014230812A8 (en) 2015-09-10
RU2018109979A (ru) 2019-02-28
AU2016204432B2 (en) 2017-12-07
CA2897618A1 (en) 2014-09-18
KR20170070270A (ko) 2017-06-21
CN105377856A (zh) 2016-03-02
JP6363120B2 (ja) 2018-07-25
CA3005112A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
EP3404032C0 (en) 2025-07-02
WO2014140073A1 (en) 2014-09-18
JP2020114814A (ja) 2020-07-30
RU2015138488A (ru) 2017-04-20
MX2015011438A (es) 2016-02-03
EP3845540A1 (en) 2021-07-07
AR095365A1 (es) 2015-10-14
CA2948765A1 (en) 2014-09-18
CA3005118A1 (en) 2014-09-18
AU2016204432A1 (en) 2016-07-21
US9303043B2 (en) 2016-04-05
CA2948763A1 (en) 2014-09-18
JP2018150298A (ja) 2018-09-27
US20140275523A1 (en) 2014-09-18
NZ711192A (en) 2019-04-26
BR112015020716A2 (pt) 2017-07-18
JP2016512209A (ja) 2016-04-25
SG10201706760YA (en) 2017-10-30
CN108929333A (zh) 2018-12-04
CA2948763C (en) 2018-04-24

Similar Documents

Publication Publication Date Title
KR101871133B1 (ko) 벤즈옥사제핀 화합물의 제조 방법
US5252584A (en) Hydroxyquinolone derivatives
EA023045B1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
EP1042317B1 (en) Indole derivatives as PKC-inhiboitors
AU2020229920A1 (en) Acryloyl-containing nuclear transport regulator and uses thereof
EP1192150A1 (en) New pharmaceutically active compounds
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
NZ614610A (en) Heterocyclic compounds for the inhibition of pask

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

Not in force date: 20210620

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210620

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000